In a nutshell This study investigated the safety and effectiveness of crizotinib (Xalkori) in advanced non-small cell lung cancer (NSCLC). They found that this treatment improved survival in advanced NSCLC. Some background Standard therapy for NSCLC involves chemotherapy and radiation. Patients with advanced NSCLC may not respond to...
Read MoreIn a nutshell This meta-analysis aimed to establish the incidence of severe and fatal side effects associated with crizotinib (Xalkori) in patients with ALK-positive non-small-cell lung cancer (NSCLC). The authors concluded that crizotinib does not increase the risk of severe or fatal side effects compared to chemotherapy. Some background The...
Read MoreIn a nutshell This review aimed to provide updated guidelines on treating non-small-cell lung cancer depending on the genetic profile of the cancer. The authors conclude that in certain types of cancers with genetic mutations (changes) drugs aimed at the specific mutation could be more beneficial than chemotherapy and other treatments. Some background...
Read More
In a nutshell The American Society of Clinical Oncology (ASCO) gathered a panel of experts to update guidelines on systemic therapy (such as chemotherapy) for stage 4 non-small cell lung cancer (NSCLC). They provided updated guidelines with recommendations for first, second and third-line systemic therapy as well as targeted therapy. Some...
Read More
In a nutshell This article evaluated best treatment options for wild-type epidermal growth factor receptor (EGFR) lung cancer. Specifically, it compared outcomes using EGFR-targeted drugs versus conventional chemotherapy. Some background The EGFR gene is responsible for building a specific protein needed by cancer cells to multiply. Mutations...
Read More
